Revvity, Inc.

RVTY

NYSE; business equipment; SIC 3826, Laboratory Analytical Instruments; CIK 0000031791

E

weakest fifth of 498 graded peers in business equipment

rank 422 of 498; percentile 84.7; sampling error 2.2 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	D percentile 76.3
Solvency	C percentile 43.7
Growth and financing	D percentile 66.0
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $12.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Feb 24, 2026 255 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$150.85 2026-11-05; market equity $16.8B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 76.3						
Gross profitability	not computable	28.7%				
latest aligned inputs end 2023-01-01; latest annual assets end 2025-12-28						
Return on invested capital	not computable	11.4%				

latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-28						
Accruals ratio	(2.8%)	(7.3%)		76.3	618	2025-12-28
Gross margin stability, five years	not computable	2.3 pts				
five consecutive annual gross margins are required						
Solvency, sleeve percentile 43.7						
Twelve-month failure probability	not computable	0.05%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	3.86	2.18		29.8	565	2025-12-28
Net debt to EBITDA	not computable	1.08x				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-28						
Interest coverage	not computable	3.77x				
latest aligned inputs end 2021-01-03; latest annual assets end 2025-12-28						
Current ratio	1.68x	2.01x		57.7	663	2025-12-28
Growth and financing, sleeve percentile 66.0						
Revenue growth, three-year compound	(4.8%)	6.4%		80.0	535	2025-12-28
Free cash flow growth, three-year compound	(5.0%)	18.0%		81.8	265	2025-12-28
Reinvestment rate	(351.2%)	13.5%		90.5	223	2025-12-28
Asset growth, three years	(4.9%)	5.1%		74.1	560	2025-12-28
Net share issuance, one year	(7.0%)	0.5%		3.4	409	2026-02-20

Among 498 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
417	Marqeta, Inc. (MQ)	83.7	E	
418	Neonode Inc. (NEON)	83.9	E	
419	Vistance Networks, Inc. (VISN)	84.1	E	
420	Magnite, Inc. (MGNI)	84.3	E	
421	Methode Electronics Inc. (MEI)	84.5	E	
422	Revvity, Inc. (RVTY)	84.7	E	
423	Cerence Inc. (CRNC)	84.9	E	
424	Socket Mobile, Inc. (SCKT)	85.1	E	fortress balance sheet
425	Pacific Biosciences OF California, Inc. (PACB)	85.3	E	short runway
426	Xperi Inc. (XPER)	85.5	E	fortress balance sheet
427	Open Text Corp. (OTEX)	85.7	E	

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	63.7%	(2.0%)	82
Distance from 52-week high	(9.0%)	(37.7%)	84
EBIT to enterprise value	1.8%	1.8%	50
Free cash flow yield	3.0%	3.0%	50

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.43	0.30	64
Sales to price	0.17	0.33	28
Composite equity issuance, five years	(1.7%)	4.2%	40
Relative strength against the sector, log excess return	0.22	(0.29)	82

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-28	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.0B
Operating cash flow, four quarters	$627.6M
Months of runway	not finite
Days since last periodic filing	87 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$244.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2.0B	2023-01-01	2023-03-01	10-K	23-000004
2	assets	us-gaap:Assets	$14.1B	2023-01-01	2024-02-27	10-K	24-000004
3	operating income	us-gaap:OperatingIncomeLoss	$300.6M	2023-12-31	2026-02-24	10-K	26-000012
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$183.0M	2023-12-31	2026-02-24	10-K	26-000012
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$3.5M	2023-12-31	2026-02-24	10-K	26-000012
6	total debt	us-gaap:LongTermDebt	$3.9B	2023-12-31	2024-02-27	10-K	24-000004
7	book equity	us-gaap:StockholdersEquity	$7.9B	2023-12-31	2026-02-24	10-K	26-000012
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$913.2M	2023-12-31	2026-02-24	10-K	26-000012
9	total debt	us-gaap:LongTermDebt	$4.4B	2023-01-01	2023-03-01	10-K	23-000004
10	book equity	us-gaap:StockholdersEquity	$7.4B	2023-01-01	2026-02-24	10-K	26-000012
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$454.4M	2023-01-01	2025-02-25	10-K	25-000009
12	net income	us-gaap:NetIncomeLoss	$241.2M	2025-12-28	2026-02-24	10-K	26-000012
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$582.9M	2025-12-28	2026-02-24	10-K	26-000012
14	assets	us-gaap:Assets	$12.2B	2025-12-28	2026-02-24	10-K	26-000012
15	assets	us-gaap:Assets	$12.4B	2024-12-29	2026-02-24	10-K	26-000012
16	current assets	us-gaap:AssetsCurrent	$2.2B	2025-12-28	2026-02-24	10-K	26-000012
17	current liabilities	us-gaap:LiabilitiesCurrent	$1.3B	2025-12-28	2026-02-24	10-K	26-000012
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$6.1B	2025-12-28	2026-02-24	10-K	26-000012
19	operating income	us-gaap:OperatingIncomeLoss	$356.6M	2025-12-28	2026-02-24	10-K	26-000012
20	book equity	us-gaap:StockholdersEquity	$7.3B	2025-12-28	2026-02-24	10-K	26-000012
21	liabilities	us-gaap:Liabilities	$4.9B	2025-12-28	2026-02-24	10-K	26-000012
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$431.8M	2023-12-31	2026-02-24	10-K	26-000012
23	operating income	us-gaap:OperatingIncomeLoss	$867.3M	2021-01-03	2023-03-01	10-K	23-000004
24	interest expense	us-gaap:InterestExpense	$49.7M	2021-01-03	2021-03-02	10-K	21-000003
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.9B	2025-12-28	2026-02-24	10-K	26-000012
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2024-12-29	2026-02-24	10-K	26-000012

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2023-12-31	2026-02-24	10-K	26-000012
28	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.3B	2023-01-01	2025-02-25	10-K	25-000009
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$73.5M	2025-12-28	2026-02-24	10-K	26-000012
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$628.3M	2024-12-29	2026-02-24	10-K	26-000012
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$86.6M	2024-12-29	2026-02-24	10-K	26-000012
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$91.3M	2023-12-31	2026-02-24	10-K	26-000012
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$81.4M	2023-12-31	2026-02-24	10-K	26-000012
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$679.8M	2023-01-01	2025-02-25	10-K	25-000009
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$85.6M	2023-01-01	2025-02-25	10-K	25-000009
36	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$405.3M	2025-12-28	2026-02-24	10-K	26-000012
37	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$268.3M	2025-12-28	2026-02-24	10-K	26-000012
38	income tax	us-gaap:IncomeTaxExpenseBenefit	$28.4M	2025-12-28	2026-02-24	10-K	26-000012
39	current assets	us-gaap:AssetsCurrent	$2.3B	2024-12-29	2026-02-24	10-K	26-000012
40	current liabilities	us-gaap:LiabilitiesCurrent	$653.1M	2024-12-29	2026-02-24	10-K	26-000012
41	assets	us-gaap:Assets	$13.6B	2023-12-31	2025-02-25	10-K	25-000009
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	111,799,374	2026-02-20	2026-02-24	10-K	26-000012
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	120,187,286	2025-02-21	2025-02-25	10-K	25-000009

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.